β-Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis.

Lymphangioleiomyomatosis (LAM) is a rare multisystem disease leading to cystic destruction of the lung parenchyma and is associated with abnormal smooth muscle proliferation affecting airways, lymphatics, and blood vessels. LAM occurs sporadically or in association with the tuberous sclerosis complex (TSC). Recent evidence demonstrates the role of aberrant β-catenin signaling in TSC. To further understand the pathogenesis of LAM and to examine the diagnostic usefulness of β-catenin, we examined protein expression in 28 pulmonary LAM cases and 10 cases of renal angiomyolipoma resected from patients with sporadic LAM. Immunohistochemical analysis was performed for established markers of LAM cells (HMB45, estrogen receptor [ER]-α, and progesterone receptor [PR]) and β-catenin. All LAM cases were positive for β-catenin and demonstrated high specificity with overall immunoreactivity superior to HMB45, ER-α, and PR. Similar expression was demonstrated in renal angiomyolipoma. Our results indicate that β-catenin is a useful marker of LAM and may be clinically useful in the diagnostic setting.

[1]  R. Yeung,et al.  The loss of tuberin promotes cell invasion through the ß-catenin pathway. , 2010, American journal of respiratory cell and molecular biology.

[2]  H. Popper,et al.  European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis , 2010, European Respiratory Journal.

[3]  V. Poletti,et al.  Cathepsin-k expression in pulmonary lymphangioleiomyomatosis , 2009, Modern Pathology.

[4]  J. Moss,et al.  Lymphatic Involvement in Lymphangioleiomyomatosis , 2008, Annals of the New York Academy of Sciences.

[5]  J. D’Armiento,et al.  Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. , 2007, Cancer research.

[6]  L. Aicher,et al.  Molecular Pathogenesis of Genetic and Inherited Diseases Aberrant (cid:1) -Catenin Signaling in Tuberous Sclerosis , 2005 .

[7]  L. Aicher,et al.  Aberrant beta-catenin signaling in tuberous sclerosis. , 2005, The American journal of pathology.

[8]  E. de Álava,et al.  Angiomyolipoma and PEComa Are Immunoreactive for MyoD1 in Cell Cytoplasmic Staining Pattern , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[9]  N. Perrimon,et al.  The Promise and Perils of Wnt Signaling Through β-Catenin , 2002, Science.

[10]  N. Perrimon,et al.  The promise and perils of Wnt signaling through beta-catenin. , 2002, Science.

[11]  D. Kwiatkowski,et al.  Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. , 2001, American journal of respiratory and critical care medicine.

[12]  A. Dwyer,et al.  Lymphangioleiomyomatosis: abdominopelvic CT and US findings. , 2000, Radiology.

[13]  S. Johnson.  Lymphangioleiomyomatosis: clinical features, management and basic mechanisms , 1999 .

[14]  S. Johnson.  Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms. , 1999, Thorax.

[15]  K. Busam,et al.  Melan-A, a new melanocytic differentiation marker. , 1999, Advances in anatomic pathology.

[16]  V. Ferrans,et al.  Immunohistochemical analysis of proteins of the Bcl-2 family in pulmonary lymphangioleiomyomatosis: association of Bcl-2 expression with hormone receptor status. , 1998, Archives of pathology & laboratory medicine.

[17]  F. Marincola,et al.  Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[18]  L. Liotta,et al.  Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). , 1997, Human pathology.

[19]  M. Satoh,et al.  Diagnosis of pulmonary lymphangioleiomyomatosis by HMB45 in surgically treated spontaneous pneumothorax. , 1995, The European respiratory journal.

[20]  P. Unger,et al.  HMB-45 reactivity in renal angiomyolipoma and lymphangioleiomyomatosis. , 1994, Archives of pathology & laboratory medicine.

[21]  G. Zamboni,et al.  Transbronchial Biopsy in Lymphangiomyomatosis of the Lung HMB45 for Diagnosis , 1993, The American journal of surgical pathology.

[22]  T. Matthews,et al.  Comparison of the use of antibodies to alpha smooth muscle actin and desmin in pulmonary lymphangioleiomyomatosis. , 1993, Journal of clinical pathology.

[23]  T. Colby,et al.  Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. , 1991, American journal of clinical pathology.

[24]  R. Coombes,et al.  Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study. , 1990, American journal of clinical pathology.

[25]  M. Colley,et al.  Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis. , 1989, The American journal of surgical pathology.